FDA’s Proposed PSAP Policy Draws Mixed Reviews

You are here

FDA’s Proposed PSAP Policy Draws Mixed Reviews

Thu, 02/20/2014
FDA’s Proposed New PSAP Policy Draws Mixed Response, but Mostly Opposed
By David H. Kirkwood
 
SILVER SPRING, MD – The U.S. Food and Drug Administration (FDA) has  more than 100, highly diverse, public comments to consider in deciding if it should implement or rethink a proposed new guidance document that it issued on November 7.
 
Anna Gilmore Hall, executive director of HLAA, comments in the article. Read Kirkwood’s article.